Clinical trial · Interventional
Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis.
Efficacy of Wholistic Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis A Randomized, Double Blinded, Placebo Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase 2, randomized, double blind, placebo controlled trial for the effectivness of wholistic turmeric supplementation on polyp burden mong patients with Familial Adenomatouse Polyposis (FAP). Fourty Patients will be randomly assigned in a 1:1 ratio to recieve treatment with 8 capsuls (2\*4 capsuls/day) of wholistic Turmeric capsules (Pukka herbs) or placebo for six months.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Familial Adenomatous Polyposis | — | UNRESOLVED | — |
| FAP | — | UNRESOLVED | — |
| FAP Gene Mutation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Other | — | UNRESOLVED |
| Wholistic Turmeric capsules | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Wholistic Turmeric capsules
- description
- Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals. Pukka's Wholistic Turmeric
- interventionNames
- Dietary Supplement: Wholistic Turmeric capsules
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Identical placebo capsules
- interventionNames
- Other: Placebo
Primary outcomes (2)
- measure
- Number of polyps
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. An established clinical diagnosis of Familial Polyposis based on accepted clinical/ endoscopic and an identified APC or MUTYH mutation 2. Age 18-70 years. 3. Willing and able to give written consent. 4. At least 5 polyps, 2mm or lrager, with at least one larger then 4mm but not more then 20mm. 5. Colonic polyp burden that can be estimated by either counting or photographing(photo or video). Exclusion criteria: 1. Pregnant or nursing women. 2. Stable does of any COX inhibitor drugs for more than 3 months prior to study entry,. 3. Concomitant severe or uncontrolled cardiovascular, hepatic, renal or metabolic disease. 4. Known allergy to curcumin. 5. Anticipated surgery within 6 months 6. Diagnosed polyps of high grade dysplasia or of adenocarcinomas in the GI on screening colonoscopy.
References
Publications (3)
- BACKGROUNDCruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1035-8. doi: 10.1016/j.cgh.2006.03.020. Epub 2006 Jun 6. PMID 16757216
- BACKGROUNDPerkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40. PMID 12050094
- BACKGROUNDPettan-Brewer C, Morton J, Mangalindan R, Ladiges W. Curcumin suppresses intestinal polyps in APC Min mice fed a high fat diet. Pathobiol Aging Age Relat Dis. 2011;1. doi: 10.3402/pba.v1i0.7013. Epub 2011 Jun 1. PMID 22953026